KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). PMID 40759981 · Trials · 2025-Aug-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis. PMID 40759562 · RMD Open · 2025-Aug-04 The study is a Phase III randomized trial of drugs (sarilumab vs. adalimumab) in humans, but it is not in oncology (it is in rheumatoid arthritis). It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.); the primary focus is biomarker analysis. Therefore, it is excluded based on the non-oncology criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. PMID 40759444 · J Immunother Cancer · 2025-Aug-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. PMID 40759441 · J Immunother Cancer · 2025-Aug-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Impact of Nurse-Led Intervention on Breast Cancer Screening and Early Detection in China: Randomized Control Trial. PMID 40849715 · Asian Pac J Cancer Prev · 2025-Aug-01 The study is an oncology randomized trial in humans with original results, but it is excluded because: 1) The intervention is non-drug (nurse-led educational intervention, not a drug-containing therapy); 2) There is no explicit Phase III/IIIb or Phase II/III designation; 3) The primary endpoint is screening behavior/awareness (behavioral outcome), not a therapeutic time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Doctor's Counselling Using Culturally Responsive Pamphlet Increased Mammogram Uptake among Malay-Muslim Women in Singapore: A Randomized Controlled Trial in a Primary Healthcare Clinic. PMID 40849697 · Asian Pac J Cancer Prev · 2025-Aug-01 The record describes a randomized trial of doctor's counselling on mammogram uptake (a screening behaviour), not a drug intervention for treating a human malignant neoplasm. It is not a Phase III/IIIb or Phase II/III trial. The primary endpoint is mammogram uptake (a screening rate), not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial. PMID 40844778 · JAMA Netw Open · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial. PMID 40815510 · JAMA Netw Open · 2025-Aug-01 The study is a randomized oncology trial with a drug intervention, but its primary and key secondary outcomes are quality-of-life and functional scales, not a formal time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Survival outcomes were mentioned only as unaffected secondary measures, not as the primary or key secondary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. PMID 40750774 · Blood Cancer J · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. PMID 40569584 · JAMA Oncol · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. PMID 40531517 · JAMA Oncol · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. PMID 40473464 · J Nucl Med · 2025-Aug-01 The study is a Phase 3, prospective, multicenter diagnostic performance trial for a PET radiotracer. While it is oncology, human, and reports original results, it fails eligibility because it is not randomized, the intervention is not a drug (it's an imaging agent), and the primary endpoints are not time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. PMID 40473463 · J Nucl Med · 2025-Aug-01 The record describes a Phase II/III prospective imaging efficacy study for a diagnostic PET radiotracer. While it is an original oncology trial in humans, it fails two critical eligibility criteria: (1) it is not randomized, and (2) the intervention is not a drug therapy with a time-to-event efficacy endpoint. The primary endpoints are diagnostic sensitivity and specificity, not OS, PFS, or other time-to-event outcomes. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium. PMID 40435111 · Clin Cancer Res · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. PMID 40392969 · Clin Cancer Res · 2025-Aug-01 This record is a secondary biomarker analysis of the E1609 Phase III trial, not the original primary result report. While it references a Phase III trial with drug intervention and time-to-event endpoints, it does not present the original trial results. Randomization is implied but not explicitly confirmed in this abstract. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial. PMID 40378056 · Clin Cancer Res · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial. PMID 40156600 · Int J Radiat Oncol Biol Phys · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study. PMID 40135473 · Int J Cancer · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Influence on Postoperative Results and Cost-effectiveness of Using Cyanoacrylate Glue for Pancreaticojejunal Anastomosis After Duodenopancreatectomy. PMID 40127250 · Pancreas · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial. PMID 40054586 · Int J Radiat Oncol Biol Phys · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic "Microboost". PMID 39855400 · Int J Radiat Oncol Biol Phys · 2025-Aug-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association of Lateral Pelvic Lymph Nodes with Disease Recurrence and Organ Preservation in Patients with Distal Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. PMID 38647132 · Ann Surg · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment. PMID 40927310 · J Immunother Precis Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. PMID 40893604 · Lancet Reg Health West Pac · 2025-Aug Study is a randomized Phase III trial extension evaluating a drug (HPV vaccine) in humans with oncology indication (cervical cancer prevention). However, the primary efficacy endpoints (lesions and persistent infection) are not standard time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) and are not reported using Kaplan-Meier or hazard ratios as primary analysis, thus failing the key time-to-event criterion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eradication of Helicobacter pylori for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT. PMID 40844182 · Health Technol Assess · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015. PMID 40842042 · Cancer Med · 2025-Aug The record describes a retrospective secondary analysis of a clinical trial (CCCG-ALL-2015) focused on the incidence and impact of acute abdomen. While the trial itself is randomized and includes time-to-event endpoints (OS, EFS), this specific report does not present the primary efficacy results of a drug-containing intervention. It is a secondary, safety/complication-focused analysis, not a primary report of the trial's definitive drug efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial. PMID 40769685 · Lancet Haematol · 2025-Aug The study is an oncology-related randomized trial in humans with original results, but it does not meet two key inclusion criteria: 1) It is not explicitly a Phase III/IIIb or Phase II/III trial (phase is not specified, and it is a single-centre study unlikely to be definitive Phase III); 2) The intervention is non-pharmacological (no drug-containing intervention). The primary endpoint is a patient-reported outcome (sexual satisfaction score) at a fixed time point, not a time-to-event endpoint like OS or PFS, and no Kaplan-Meier or HR analysis is reported. Therefore, it is ineligible for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of an online mindfulness program (MindOnLine) to reduce fear of recurrence in people living with-and beyond-breast, prostate or colorectal cancer: a randomized controlled trial. PMID 40756964 · EClinicalMedicine · 2025-Aug The record describes a randomized trial in oncology patients, but it does not meet the eligibility criteria: the trial phase is not specified, the intervention is a non-drug psychological program, and the endpoints are not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. PMID 40755069 · Eur J Neurol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Management of Chemotherapy-induced Oral Mucositis in Gastrointestinal Malignancies: Evidence From Randomized Controlled Trails. PMID 40750413 · Anticancer Res · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China. PMID 40748918 · PLoS Med · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis. PMID 40747769 · Cancer Med · 2025-Aug The record is a post-randomization analysis from a randomized trial. It reports time-to-event outcomes (PCSM and ACM) but does not establish a Phase III/IIIb or Phase II/III trial design or a drug-containing intervention as required. The analysis is subgroup-focused by comorbidity status.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation. PMID 40740293 · EClinicalMedicine · 2025-Aug The study is a target trial emulation of a non-randomized comparison of antiretroviral regimens in HIV patients, focusing on clinical outcomes including cancer. It is not a randomized controlled trial for an oncologic indication with a standard oncologic time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The COMFORT Trial: A Randomised Control Trial Comparing Group-Based COMpassion-FOcused Therapy Techniques and Breathing Pattern ReTraining With Treatment as Usual on the Psychological Functioning of Patients Diagnosed With Cancer Recurrence. PMID 40736172 · Cancer Med · 2025-Aug The study is a randomized, original-result oncology trial in humans, but it fails two key eligibility criteria: 1) the primary endpoint is distress (a patient-reported quality-of-life measure), not a time-to-event efficacy endpoint like OS or PFS, and 2) the intervention is purely psychological/behavioral, with no drug component. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma. PMID 40714516 · ESMO Open · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer. PMID 40714513 · ESMO Open · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. PMID 40691368 · Nat Med · 2025-Aug The record is a published erratum for a trial, not an original result report. Additionally, there is no evidence in the provided metadata of a time-to-event efficacy endpoint being reported.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). PMID 40682909 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical utility of photodynamic diagnosis with 5-aminolevulinic acid hydrochloride for detecting carcinoma in situ independent of urine cytology classification. PMID 40680915 · Photodiagnosis Photodyn Ther · 2025-Aug This is a human oncology Phase III trial with original results. However, it is excluded because it is not randomized, the intervention is a diagnostic technique (photodynamic diagnosis) rather than a drug-containing therapy, and the primary endpoint is diagnostic accuracy, not a time-to-event efficacy outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clearing the air: Empowering high-risk adults with digital tools for smoking cessation and lung cancer screening adoption. PMID 40669310 · Lung Cancer · 2025-Aug The study meets criteria for being an original, randomized, human oncology trial, but it is excluded because it is not a Phase III/IIIb or Phase II/III trial, lacks a primary time-to-event efficacy endpoint, and does not have a drug-containing intervention as defined by the protocol (nicotine replacement is considered part of a behavioral/digital intervention bundle, not a standalone drug intervention for cancer treatment).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). PMID 40669093 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preliminary data on the oncological safety of autologous fat transfer (AFT) for total breast reconstruction from the BREAST trial. PMID 40652913 · J Plast Reconstr Aesthet Surg · 2025-Aug 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. PMID 40651932 · Eur Urol Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. PMID 40630018 · Alcohol Clin Exp Res (Hoboken) · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis. PMID 40616902 · EBioMedicine · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
"A 10-years follow-up of Photodynamic Therapy for nodular basal cell carcinoma: a randomized comparing the effectiveness of Aminolevulinic acid-PDT, Methyl aminolevulinate-PDT, and surgery". PMID 40614840 · Photodiagnosis Photodyn Ther · 2025-Aug While the study is a randomized oncology trial with time-to-event endpoints, it fails two critical eligibility criteria: 1) The intervention (Photodynamic Therapy) is not considered a 'drug-containing intervention' as defined by the cohort (requiring cytotoxic, hormonal, or targeted agents). 2) The phase of the trial is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Impact of Machine Learning Mortality Risk Prediction on Clinician Prognostic Accuracy and Decision Support: A Randomized Vignette Study. PMID 40613383 · Med Decis Making · 2025-Aug Study is a randomized vignette survey evaluating a machine learning tool's impact on clinician prognostic accuracy in mNSCLC. It is not a clinical trial of a drug intervention with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer. PMID 40608178 · Breast Cancer Res Treat · 2025-Aug The study is a randomized trial in human breast cancer survivors, but it is a Phase II/III trial? No, the abstract does not specify phase, but it is a small exercise physiology study (n=32), not a definitive drug trial. It has no drug intervention (exercise-only), and the endpoints are in vitro cell growth and serum myokine levels, not a time-to-event clinical outcome like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Robotic Versus Laparoscopic Surgery for Colorectal Cancer: A Trial Sequential Meta-Analysis of Randomized Trials. PMID 40524569 · J Laparoendosc Adv Surg Tech A · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512). PMID 40503645 · J Dermatol · 2025-Aug The record describes an ancillary analysis of a Phase III randomized trial focusing on skin toxicity markers and disease control rate (a response metric, not a time-to-event outcome). The primary/key secondary endpoint of the parent trial is not specified, and this report does not present Kaplan-Meier curves or hazard ratios for OS, PFS, or other time-to-event endpoints.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -